Company profile: Paratek Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies based on novel tetracycline chemistry, including NUZYRA, an FDA-approved tetracycline-class antibiotic for adults with CABP and ABSSSI caused by select susceptible microorganisms, and SEYSARA, an FDA-approved oral therapy for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older.
Products and services
- SEYSARA: An FDA-approved oral therapy that treats inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 years and older
- NUZYRA: An FDA-approved tetracycline-class antibiotic for treating adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by select susceptible microorganisms
- Novel Tetracycline Chemistry Therapeutics Development: Paratek develops and commercializes innovative therapies founded on novel tetracycline chemistry, a tetracycline-based capability central to its biopharmaceutical work
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Paratek Pharmaceuticals
DDL
HQ: The Netherlands
Website
- Description: Provider of diagnostic solutions in molecular virology, bioinformatics, molecular bacteriology, and pathology, supporting clinical trials globally across five continents. Offers infectious disease and vaccine development expertise, oncology trial support, rare disease cell and gene therapy operations, biologics and biosimilars services from preclinical to post-market, and customized kit building for sample integrity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DDL company profile →
Micronics
HQ: United States
Website
- Description: Provider of near-patient in vitro diagnostic products for disease diagnosis, prognosis, and treatment monitoring in the United States and internationally, including the PanNAT molecular diagnostic system, a point-of-care testing instrument.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micronics company profile →
Emergent BioSolutions
HQ: United States
Website
- Description: Provider of medical countermeasures for biological and chemical threats, developing, manufacturing, and delivering products including NARCAN® Nasal Spray to rapidly reverse opioid overdose; BioThrax® and CYFENDUS™ anthrax vaccines; ACAM2000® smallpox vaccine; TEMBEXA® antiviral for smallpox; and EbangaTM therapeutic antibody for Ebola virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergent BioSolutions company profile →
Insmed
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines for rare diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insmed company profile →
ContraFect
HQ: United States
Website
- Description: Provider of biotechnology research focused on monoclonal antibodies to treat life-threatening infectious diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ContraFect company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Paratek Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Paratek Pharmaceuticals
2.2 - Growth funds investing in similar companies to Paratek Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Paratek Pharmaceuticals
4.2 - Public trading comparable groups for Paratek Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →